- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05538351
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute Kidney Injury (AKI) is the sudden and recent reduction in kidney function. This can be detected by measuring a rise in blood creatinine level or from a reduction in urine. Reasons for developing AKI, include dehydration, low blood pressure, medication and infection. When the kidneys stop working, there can be a build-up of toxins and fluid. It is extremely important to identify a patient's fluid status as too little can cause further damage to the kidneys and too much can be harmful. Assessment is varied and often inaccurate and there needs to be a standard approach to fluid assessment.
Aim:
To develop an Enhanced Fluid Assessment Tool for patients with AKI.
Workstream 1:
Aim: To identify what methods are useful to assess fluid in a patient with AKI. The fluid assessment techniques that are useful and are used, bioimpedance and patient reported signs and symptoms.
Workstream 2:
Aim: To identify the best methods of determining fluid status in a patient with AKI The findings from Workstream 1 will be used to rank the most useful fluid assessment techniques. This will lead to the development of the enhanced fluid assessment tool.
Workstream 3:
Aim: To assess if the tool is practical and clinically useful in determining a patient's fluid status.
The terminology and language will be reviewed and the tool will be used to assess patients and to determine the patients fluid status.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Stevenage, United Kingdom
- East and North Hertfordshire NHS Trust, Lister Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Workstream 1 and 3 (phase 3):
Patients who will be included in the study will be Adult patients (over 18 years old) identified as having an acute kidney injury (AKI) within 72 hours of admission to hospital.
Workstream 2:
Experts in fluid assessment (Doctors, Nurses and AHPs). Persons included will be experts in their field of practice and have a recognised expertise in fluid assessment.
Workstream 3:
Phase 1: Experts in fluid assessment (Doctors, Nurses and AHPs). Phase 2: Staff nurses currently working on a clinical ward.
Exclusion Criteria:
- Patients who have kidney failure requiring dialysis or who are being conservatively managed.
- Patients who are receiving end of Life (EoL) care.
- Patients who have a pacemaker as this interferes with bioimpedance (WS1+3).
- There is no baseline creatinine.
- The patient has acquired an AKI 72 hours after admission to hospital.
- The patient has acute coronary syndrome
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Fluid assessment
All patients enrolled in this study will have a clinical assessment to identify hydration status, patient reported signs and symptoms of hydration and Bioimpedance using the Body composition Monitor (BCM).
|
The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To identify the components of clinical assessment deemed useful in determining fluid status in patients with AKI.
Time Frame: Within 72 hours of admission
|
Identifying the components of a volume assessment as defined in RCP (2015) Acute care toolkit and a scoping review on fluid assessment.
Assessment includes; physiological parameters including blood pressure, weight changes, and physical examination, including identifying any signs of oedema or dehydration and history taking.
|
Within 72 hours of admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To identify fluid status of patients with AKI using multiple assessments, including Bioimpedance, objective and subjective clinical assessments.
Time Frame: Within 72 hours of admission
|
Bioimpedance measures fluid status and location of this fluid within the body.
|
Within 72 hours of admission
|
|
To identify patient-focussed signs and symptoms of hydration in AKI
Time Frame: Within 72 hours of admission
|
The patient with acute kidney injury will be asked to describe their signs and symptoms relating to acute kidney injury.
|
Within 72 hours of admission
|
|
To evaluate whether fluid status of patients is related to: Stage of AKI, Cause of AKI, Length of stay, NEWS2 Measurements
Time Frame: At 30 days after admission
|
To identify descriptive data from the patients medical notes.
|
At 30 days after admission
|
|
To evaluate whether fluid status of patients is related to: Physical assessment (JVP, oedema, skin, respiratory, lying and standing BP, passive leg raise), Blood results: urea and creatinine, electrolytes, albumin, haemoglobin and bicarbonate.
Time Frame: Within 72 hours of admission
|
Comparison between patients in different fluid status groups will be compared using t-tests (or non-parametric comparisons), or Chi squared (χ2) tests.
Multi variable models will be explored to evaluate the relationship of measured variables to fluid status using logistic models.
|
Within 72 hours of admission
|
|
To evaluate whether fluid status is related to: Fluid balance chart/ trends and documentation (positive or negative balance) , Weight trends, Charlson Co-morbidity index
Time Frame: At 30 days since admission
|
A multivariate analysis of clinical characteristics (specifically as listed in the primary objective) to investigate their predictive effect for mortality at 30 days.
Variables that are significant in univariate models at the 10% level will be then included in a multivariable regression analysis.
|
At 30 days since admission
|
|
To evaluate whether fluid status is related to: Outcome: Renal Replacement therapy (RRT) during admission/ Recovery of kidney / dialysis dependence at 30 days/ Intensive care admission • Mortality (hospital 30-days) • Readmission (within 30 days)
Time Frame: At 30 days after admission
|
A multivariate analysis of clinical characteristics (specifically as listed in the primary objective) to investigate their predictive effect for mortality at 30 days.
Variables that are significant in univariate models at the 10% level will be then included in a multivariable regression analysis.
|
At 30 days after admission
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Natalie Pattison, East and North Herts
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolic Diseases
- Body Weight
- Respiratory Tract Diseases
- Lung Diseases
- Renal Insufficiency
- Water-Electrolyte Imbalance
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Hypertension
- Pulmonary Edema
- Acute Kidney Injury
- Dehydration
- Hypotension
- Body Weight Changes
- Edema
- Hypovolemia
- Signs and Symptoms
Other Study ID Numbers
- HSK/PGR/NHS/02973
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
Hospital Civil de GuadalajaraNot yet recruitingAcute Kidney Disease | Acute Kidney Injury (AKI) | Acute Kidney Injuries
-
Sanliurfa Mehmet Akif Inan Education and Research...CompletedIn Acute Kidney InjuryTurkey (Türkiye)
-
University Hospital, GhentWithdrawn
-
Chang Gung Memorial HospitalConmed Pharmaceutical & Bio-Medical CorporationRecruitingAcute Kidney Disease | Acute Kidney Injury (AKI)Taiwan
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
Clinical Trials on Body Composition Monitor (BCM)
-
Francisco MaduellFresenius Medical Care EuropeCompleted
-
Medical University of WarsawCompletedArterial Calcification | Aortic Stiffness | Complication of Hemodialysis | Arteriopathic DiseasePoland
-
Grigore T. Popa University of Medicine and PharmacyCompleted
-
Ege UniversityFresenius Medical Care North AmericaCompletedLeft Ventricular HypertrophyTurkey
-
Medical University of ViennaCompletedFluid Shifts | Body Fluid CompartmentsAustria
-
Medical University of WarsawCompletedEnd Stage Renal Failure on Dialysis | Cardiac Output, Low | Body Fluid Retention | ImpedancePoland
-
RenJi HospitalCompletedEnd Stage Renal DiseaseChina
-
University Hospital, AntwerpRecruitingBody Weight Changes | Children, Only | Fluid and Electrolyte ImbalanceBelgium
-
Medical University of ViennaRecruitingLiver Fibrosis | NAFLD/MAFLD | CMRAustria